within Pharmacolibrary.Drugs.ATC.C;

model C03CA02
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 2.8833333333333334e-05,
    adminDuration  = 600,
    adminMass      = 2 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00025,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.03333333333333333,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.00029,
    k12             = 2.05,
    k21             = 2.05
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C03CA02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Bumetanide is a potent loop diuretic primarily used for the treatment of edema associated with congestive heart failure, hepatic and renal diseases. It is an approved drug in current clinical use and works by inhibiting the Na-K-2Cl symporter in the thick ascending limb of the loop of Henle, promoting diuresis.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult male volunteers following single oral dose administration.</p><h4>References</h4><ol><li><p>Holazo, AA, et al., &amp; Parsonnet, M (1984). Pharmacokinetics of bumetanide following intravenous, intramuscular, and oral administrations to normal subjects. <i>Journal of pharmaceutical sciences</i> 73(8) 1108–1113. DOI:<a href=\"https://doi.org/10.1002/jps.2600730821\">10.1002/jps.2600730821</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/6491914/\">https://pubmed.ncbi.nlm.nih.gov/6491914</a></p></li><li><p>Griffin, M, et al., &amp; Testani, JM (2020). Empagliflozin in Heart Failure: Diuretic and Cardiorenal Effects. <i>Circulation</i> 142(11) 1028–1039. DOI:<a href=\"https://doi.org/10.1161/CIRCULATIONAHA.120.045691\">10.1161/CIRCULATIONAHA.120.045691</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32410463/\">https://pubmed.ncbi.nlm.nih.gov/32410463</a></p></li><li><p>Lee, SH, et al., &amp; Kim, ND (1994). Pharmacokinetics and pharmacodynamics of bumetanide after intravenous and oral administration to rats: absorption from various GI segments. <i>Journal of pharmacokinetics and biopharmaceutics</i> 22(1) 1–17. DOI:<a href=\"https://doi.org/10.1007/BF02353407\">10.1007/BF02353407</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8027946/\">https://pubmed.ncbi.nlm.nih.gov/8027946</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C03CA02;
